Clinical trial
A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV16/18-Positive Women After Vaccination With 9vHPV, a Multivalent L1 Virus-like Particle Vaccine, Evaluated in Cervical, Anal and Oral Samples Obtained After One, Two, and Three Vaccine Doses (RIFT-HPV1/RIFT-HPV2)
NCT05334706 is registered in ClinicalTrials.gov with Miquel Angel Pavon Ribas as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV16/18-Positive Women After Vaccination With 9vHPV, a Multivalent L1 Virus-like Particle Vaccine, Evaluated in Cervical, Anal and Oral Samples Obtained After One, Two, and Three Vaccine Doses (RIFT-HPV1/RIFT-HPV2)
- Lead sponsor
- Miquel Angel Pavon Ribas
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- September 13, 2022
- Completion date
- December 31, 2026
- Enrollment
- 69 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cervical intraepithelial neoplasia grade i/ ii/ iii (cin i/ii/iii), high-risk hpv, hpv-16/ 18, human papillomavirus (hpv) infections